Industries > Pharma > Next-Generation Biologics Market Forecast to 2029

Next-Generation Biologics Market Forecast to 2029

Revenue Forecasts and R&D Trends for Therapeutic Antibody Technologies, Insulins, Growth Hormones, Recombinant Coagulation Factors and Regenerative Medicine

PUBLISHED: 29 November 2019
PAGES: 296
PRODUCT CODE: PHA0621

Clear
WOOCS 2.2.1

The global next-generation biologics market is estimated to have reached $3.2bn in 2018. The market is expected to grow at a CAGR of 19.8% in the first half of the forecast period.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 296-page report you will receive 181 charts– all unavailable elsewhere.

The 296-page report provides clear detailed insight into the next-generation biologics market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Next-Generation Biologics Market forecast to 2029

• Revenue forecasts for the Next-Generation Biologics Market by Sector to 2029:
• Regenerative Medicine: Stem Cell Therapies, Tissue Engineering, Gene Therapies
• Next-Generation Antibody Therapies: ADC, Engineered Antibodies, Bispecific Antibodies
• Next-Generation Antibody Fragments & ALPs
• Next-Generation Insulin: Oral Insulin, Ultra- Rapid Acting Insulin, Ultra-Long Acting Insulin
• Next-Generation Growth Hormones
• Next-Generation Coagulating Factors
• Others

Next-Generation Biologics Market Forecast to 2029

• Revenue forecasts for the Next-Generation Biologics Market Forecast by Region to 2029:

North America:
• U.S.
• Canada

Europe:
• Germany
• UK
• France
• Italy
• Spain

Asia-Pacific:
• Japan
• China
• India

RoW
• Brazil
• Mexico
• Russia
• South Africa

• Profiles of the selected leading companies:
• AbbVie
• Amgen
• Eli Lilly
• GSK
• Novo Nordisk
• Roche/ Genentech
• Sanofi Aventis
• Seattle Genetics

• The report also includes a STEP Analysis of the Next-Generation Biologics market.

• Key questions answered by this report:
• How is the next-generation biologics therapies market evolving?
• What is driving and restraining the next-generation biologics market?
• What are the market shares of segments of the overall next-generation biologics market in 2018?
• How will each next-generation biologics segment grow over the forecast period and how much revenue will these submarkets account for by 2029?
• How will the market shares for next-generation biologics therapies submarkets develop to 2029?
• Which therapies can succeed and what are their revenue potentials?
• What will be the main sales drivers for the overall market to 2029?
• How will political and regulatory factors influence the regional markets and other submarkets?
• How will the market shares of the regional markets change by 2029 and which geographical region will lead the market by 2029?
• How will the industry evolve during the period between 2019 and 2029?

Visiongain’s study is intended for anyone requiring commercial analyses for the next-generation biologics Market. You find data, trends and predictions.

Buy our report today Next-Generation Biologics Market Forecast to 2029: Revenue Forecasts and R&D Trends for Therapeutic Antibody Technologies, Insulins, Growth Hormones, Recombinant Coagulation Factors and Regenerative Medicine.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Next-Generation Biologics Market Forecast to 2029


Download sample pages

Complete the form below to download your free sample pages for Next-Generation Biologics Market Forecast to 2029


Latest Pharma news

Visiongain Publishes Plasma Therapy Market Report 2021-2031

The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.

26 November 2020

READ

Visiongain Publishes Precision Cancer Diagnostic Test Market Report 2021-2031

Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.

26 November 2020

READ

Visiongain Publishes Top 50 Biosimilar Drug Manufacturers 2021

Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.

25 November 2020

READ

Visiongain Publishes Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031

Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth

24 November 2020

READ

Categories

Category